A pilot study linking endothelial injury in lungs and kidneys in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 11, 2017, Pages 1464-1476

  Polverino, Francesca ^a,b,c   Laucho Contreras, Maria E ^d   Petersen, Hans ^b   Bijol, Vanesa ^a   Sholl, Lynette M ^a   Choi, Mary E ^e   Divo, Miguel ^a,b   Pinto Plata, Victor ^a,b   Chetta, Alfredo ^c   Tesfaigzi, Yohannes ^b   Celli, Bartolomé R ^a,b   Owen, Caroline A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cigarette smoke; Comorbidities; COPD; Endothelium; Kidney

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CASPASE 3; CIGARETTE SMOKE; CREATININE; ENALAPRIL;

AGED; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CELL; KIDNEY INJURY; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ENDOTHELIUM; LUNG INJURY; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOKING; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENDOTHELIUM; KIDNEY; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM; FEMALE; HUMANS; KIDNEY; LUNG; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85020181496     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201609-1765OC     Document Type: Article

References (56)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773.
2. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
3. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:549-555.
4. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, Penno G. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004;24:2414-2419.
5. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7: 930-937.
6. Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander? Diabetes Care 2008;31:S194-S201.
7. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
8. Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008;26:97-102.
9. Casanova C, de Torres JP, Navarro J, Aguirre-Jaíme A, Toledo P, Cordoba E, Baz R, Celli BR. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:1004-1010.
10. Kaysoydu E, Arslan S, Yildiz G, Candan F. Factors related to microalbuminuria in patients with chronic obstructive pulmonary disease. Adv Clin Exp Med 2014;23:749-755.
11. Romundstad S, Naustdal T, Romundstad PR, Sorger H, Langhammer A. COPD and microalbuminuria: a 12-year follow-up study. Eur Respir J 2014;43:1042-1050.
12. Chandra D, Stamm JA, Palevsky PM, Leader JK, Fuhrman CR, Zhang Y, Bon J, Duncan SR, Branch RA, Weissfeld J, et al. The relationship between pulmonary emphysema and kidney function in smokers. Chest 2012;142:655-662.
13. Incalzi RA, Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V; Extrapulmonary Consequences of COPD in the Elderly Study Investigators. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010;137:831-837.
14. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, Ockene JK, Prentice RL, Speizer FE, Thun MJ, et al. Smoking and mortality: beyond established causes. N Engl J Med 2015;372: 631-640.
15. Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta 2012; 1820:663-671.
16. Wu L, Ma L, Nicholson LF, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011;105:329-336.
17. Sambamurthy N, Leme AS, Oury TD, Shapiro SD. The receptor for advanced glycation end products (RAGE) contributes to the progression of emphysema in mice. PLoS One 2015;10: e0118979.
18. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008;295:H491-H498.
19. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996;45:S77-S80.
20. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992;19:330-340.
21. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003;26:2421-2425.
22. Polverino F, Laucho-Contreras ME, Bijol V, Pinto-Plata V, Divo M, Choi ME, Sholl L, Petersen H, Tesfaigzi Y, Celli B, et al. Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD) [abstract]. Am J Respir Crit Care Med 2016;193:A6740.
23. Sood A, Stidley CA, Picchi MA, Celedón JC, Gilliland F, Crowell RE, Belinsky SA, Tesfaigzi Y. Difference in airflow obstruction between Hispanic and non-Hispanic white female smokers. COPD 2008;5: 274-281.
24. Bruse S, Sood A, Petersen H, Liu Y, Leng S, Celedón JC, Gilliland F, Celli B, Belinsky SA, Tesfaigzi Y. New Mexican Hispanic smokers have lower odds of chronic obstructive pulmonary disease and less decline in lung function than non-Hispanic whites. Am J Respir Crit Care Med 2011;184:1254-1260.
25. Laucho-Contreras ME, Taylor KL, Mahadeva R, Boukedes SS, Owen CA. Automated measurement of pulmonary emphysema and small airway remodeling in cigarette smoke-exposed mice. J Vis Exp 2015; 16:52236.
26. Laucho-Contreras ME, Polverino F, Gupta K, Taylor KL, Kelly E, Pinto- Plata V, Divo M, Ashfaq N, Petersen H, Stripp B, et al. Protective role for club cell secretory protein-16 (CC16) in the development of chronic obstructive pulmonary disease. Eur Respir J 2015;45: 1544-1556.
27. Polverino F, Doyle-Eisele M, McDonald J, Wilder JA, Royer C, Laucho- Contreras M, Kelly EM, Divo M, Pinto-Plata V, Mauderly J, et al. A novel nonhuman primate model of cigarette smoke-induced airway disease. Am J Pathol 2015;185:741-755.
28. White KE, Bilous RW; Diabiopsies Study Group. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004;19:1437-1440.
29. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56:2155-2160.
30. van Gestel YR, Chonchol M, Hoeks SE, Welten GM, Stam H, Mertens FW, van Domburg RT, Poldermans D. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol Dial Transplant 2009;24: 2763-2767.
31. Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014;40:416-421.
32. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
33. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol 2002;13:2363-2370.
34. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-1185.
35. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, Bruijn JA. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003;14: 2063-2071.
36. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106: 1311-1319.
37. Tuder RM, Kasahara Y, Voelkel NF. Inhibition of vascular endothelial growth factor receptors causes emphysema in rats. Chest 2000;117 (Suppl. 1):281S.
38. Lhotta K, Rumpelt HJ, König P, Mayer G, Kronenberg F. Cigarette smoking and vascular pathology in renal biopsies. Kidney Int 2002; 61:648-654.
39. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB, Litzky L, Coxson HO, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011;365: 1567-1575.
40. Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev 2011;20:23-33.
41. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004;53: 166-172.
42. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997;94:13915-13920.
43. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280:E685-E694.
44. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716-3727.
45. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011;12:37.
46. Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, Sylvia JS, Ziniti J, Laird NM, et al.; NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med 2014;2: 214-225.
47. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, et al.; TESRA and ECLIPSE Investigators. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:948-957.
48. Petersen H, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest 2014;145: 695-703.
49. Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:715-720.
50. Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos C, Ryan JW, Catravas JD. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation 1999;99:1593-1599.
51. Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez- Villalobos RA, Shen XZ, Fuchs S, Touyz RM. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 2012; 65:1-46.
52. Arcaro G, Zenere BM, Saggiani F, Zenti MG, Monauni T, Lechi A, Muggeo M, Bonadonna RC. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care 1999;22:1536-1542.
53. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Jerums G, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-3282.
54. Shrikrishna D, Tanner RJ, Lee JY, Natanek A, Lewis A, Murphy PB, Hart N, Moxham J, Montgomery HE, Kemp PR, et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. Chest 2014;146:932-940.
55. Curtis KJ, Meyrick VM, Mehta B, Haji GS, Li K, Montgomery H, Man WD, Polkey MI, Hopkinson NS. Angiotensin-converting enzyme inhibition as an adjunct to pulmonary rehabilitation in COPD. Am J Respir Crit Care Med 2016;194:1349-1357.
56. Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, Heels- Ansdell DM, Erak M, Bragaglia PJ, Tamari IE, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010;182:673-678.